Skip to main content

Ligand Directed NIR-based Theranostic Prodrugs for Prostate Cancer

Project description

Ligand-directed NIR-based theranostic prodrugs for prostate cancer

Prostate cancer is currently the most common cancer in men and remains the leading cause of death. Current strategies still carry severe side effects and offer limited benefits to the patient, associated with non-specific delivery of an anticancer drug to the target tissue. The EU-funded ClickandTreatCancer project is working on developing a strategy to deliver anticancer drugs selectively to prostate cancer cells while monitoring in real-time drug release and efficacy in vivo. The project entails the creation of a protocol based on a DT-diaphorase-activated, DUPA-guided model combined with cancer cell elimination by near-infrared (NIR) light-regulated theranostic strategy. The technology shows great promise in that it can easily be adapted for the treatment of other cancer types.

Coordinator

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Net EU contribution
€ 159 815,04
Address
Avenida Prof Egas Moniz
1649 028 Lisboa
Portugal

See on map

Region
Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa
Activity type
Research Organisations
Other funding
€ 0,00